JP2010508364A - 樹状細胞腫瘍注射治療及び関連するワクチン - Google Patents

樹状細胞腫瘍注射治療及び関連するワクチン Download PDF

Info

Publication number
JP2010508364A
JP2010508364A JP2009535441A JP2009535441A JP2010508364A JP 2010508364 A JP2010508364 A JP 2010508364A JP 2009535441 A JP2009535441 A JP 2009535441A JP 2009535441 A JP2009535441 A JP 2009535441A JP 2010508364 A JP2010508364 A JP 2010508364A
Authority
JP
Japan
Prior art keywords
cells
patient
tumor
activated
tumor tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009535441A
Other languages
English (en)
Japanese (ja)
Inventor
賢一郎 蓮見
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hasumi International Research Foundation
Original Assignee
Hasumi International Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hasumi International Research Foundation filed Critical Hasumi International Research Foundation
Publication of JP2010508364A publication Critical patent/JP2010508364A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009535441A 2006-10-31 2007-10-31 樹状細胞腫瘍注射治療及び関連するワクチン Pending JP2010508364A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85590506P 2006-10-31 2006-10-31
PCT/US2007/083161 WO2008063837A2 (fr) 2006-10-31 2007-10-31 Thérapie par injection dans des tumeurs des cellules dendritiques et vaccin associé

Publications (1)

Publication Number Publication Date
JP2010508364A true JP2010508364A (ja) 2010-03-18

Family

ID=39430435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535441A Pending JP2010508364A (ja) 2006-10-31 2007-10-31 樹状細胞腫瘍注射治療及び関連するワクチン

Country Status (3)

Country Link
EP (1) EP2091334A4 (fr)
JP (1) JP2010508364A (fr)
WO (1) WO2008063837A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961957B2 (en) * 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
KR20260036555A (ko) * 2023-07-05 2026-03-17 이뮤니티바이오, 인크. 성분채집 물질 중간체로부터 면역 이펙터 세포의 생체외 생성

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009397A2 (fr) * 2003-02-21 2005-02-03 Hasumi Llc (Dba Shukokai International) Adjuvant de vaccin à base de lymphocytes humains
WO2006033991A1 (fr) * 2004-09-17 2006-03-30 Hasumi International Research Foundation Thérapie par injection de cellules dendritiques dans une tumeur (dcti)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082806A1 (en) * 2001-04-27 2003-05-01 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated T cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009397A2 (fr) * 2003-02-21 2005-02-03 Hasumi Llc (Dba Shukokai International) Adjuvant de vaccin à base de lymphocytes humains
WO2006033991A1 (fr) * 2004-09-17 2006-03-30 Hasumi International Research Foundation Thérapie par injection de cellules dendritiques dans une tumeur (dcti)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5009020417; ＣＨＩ: 'ＣＯＭＢＩＮＡＴＩＯＮ　ＯＦ　ＣＯＮＦＯＲＭＡＬ　ＲＡＤＩＯＴＨＥＲＡＰＹ　ＡＮＤ　ＩＮＴＲＡＴＵＭＯＲＡＬ　ＩＮＪＥＣＴＩＯＮ　以下備考' ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＴＨＥＲＡＰＹ Ｖ２８　Ｎ２, 2005, Ｐ１２９-１３５ *
JPN6013001417; ＭＯＲＩＳＡＫＩ，Ｔ．　ｅｔ　ａｌ: 'Ｃｏｍｂｉｎｅｄ　ｉｍｍｕｎｏｔｈｅｒａｐｙ　ｗｉｔｈ　ｉｎｔｒａｃａｖｉｔａｌ　ｉｎｊｅｃｔｉｏｎ　ｏｆ　ａｃｔｉｖａｔｅｄ　ｌｙｍｐｈｏｃｙｔｅｓ，　ｍｏｎｏｃｙｔｅ-ｄｅｒｉｖｅｄ　ｄｅｎｄｒｉ' Ａｎｔｉｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．２３，　Ｎｏ．６ａ, 2003, ｐ．４４５９-６５ *
JPN6013001420; ＳＡＴＯ，Ｔ．　ｅｔ　ａｌ: 'Ｃｏｍｂｉｎａｔｉｏｎ　ｏｆ　ｍｏｎｏｃｙｔｅ-ｄｅｒｉｖｅｄ　ｄｅｎｄｒｉｔｉｃ　ｃｅｌｌｓ　ａｎｄ　ａｃｔｉｖａｔｅｄ　Ｔ　ｃｅｌｌｓ　ｗｈｉｃｈ　ｅｘｐｒｅｓｓ　ＣＤ４０　ｌｉｇａｎｄ：　ａ　ｎ' Ｃａｎｃｅｒ　Ｉｍｍｕｎｏｌ　Ｉｍｍｕｎｏｔｈｅｒ Ｖｏｌ．５３，　Ｎｏ．１, 2004, ｐ．５３-６１ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法
US10751372B2 (en) 2008-05-02 2020-08-25 Mirror Biologics, Inc. Vaccine compositions and methods
US12233091B2 (en) 2008-05-02 2025-02-25 Mirror Biologics, Inc. Vaccine compositions and methods

Also Published As

Publication number Publication date
EP2091334A2 (fr) 2009-08-26
WO2008063837A3 (fr) 2008-09-18
EP2091334A4 (fr) 2010-02-03
WO2008063837A9 (fr) 2008-08-07
WO2008063837A2 (fr) 2008-05-29

Similar Documents

Publication Publication Date Title
Doshi et al. Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy
JP7656350B2 (ja) アンチセンスを用いて癌を治療するための方法及び組成物
CN113613673A (zh) 用于治疗胰腺癌的药物组合物
JP2005515781A (ja) 機能樹状細胞への単球の分化を誘導するための方法およびかかる樹状細胞を含む免疫療法組成物
JP2005523277A (ja) 癌の治療
EP2787005A1 (fr) Thérapie immunitaire contre le cancer ciblé
JP2024019229A (ja) 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法
US20080160050A1 (en) Dendritic cell tumor injection therapy and related vaccine
JP2012229243A (ja) 癌治療用ワクチンの製造方法
JP2004531496A (ja) 樹状細胞の成熟を誘導するグラム陰性細菌膜画分の使用方法
JP2010508364A (ja) 樹状細胞腫瘍注射治療及び関連するワクチン
Lozano et al. Technical challenges in the manufacture of dendritic cell cancer therapies
ES2927913B2 (es) Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
HK40112216A (en) Methods and compositions for treating cancers using antisense
US20240024443A1 (en) Augmentation of survivin modified mrna vaccine efficacy using dendritic cells
HK40072988A (en) Activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
JP5084012B2 (ja) イディオタイプ抗原用担体およびそれを用いたイディオタイプワクチン
WO2011068491A1 (fr) Vaccination tumorale combinée à une transplantation de cellules hématopoïétiques (hct) pour cancérothérapie
HK40022361A (en) Compositions for treating cancers using antisense
HK40022361B (en) Compositions for treating cancers using antisense
Akiyama et al. Retrospective analysis of the clinical efficacy of a dendritic cell-based cancer vaccine in patients with advanced or recurrent breast cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130419

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130730